JAK2 and Venous thrombosis: A separate analysis of venous TFS also disclosed higher risk in JAK2 and MPL-mutated patients, when compared with TN and type 1/type 1-like CALR-mutated (p = 0.03 and 0.14, respectively, HR 4.9, 95% CI 1.2–20.3 and HR 1.7, 95% CI 0.8–3.5) (Fig. 3b); additionally, we observed a trend for higher risk of venous thrombosis among type 1/type 1-like CALR and type 2/type 2-like CALR-mutated when compared with TN cases; p = 0.17 and p = 0.08, respectively, HR 2.9, 95% CI 0.6–13.3 and HR 3.9, 95% CI 0.8–17.9 (Table 4).